Marketdash
Back to News

Five Stocks in the Spotlight as Earnings Season Continues

MarketDash Editorial Team
10 hours ago
With stock futures pointing higher Monday morning, investors are watching several companies reporting earnings results, including MindWalk Holdings, Navan, and Champions Oncology, while argenx deals with clinical trial setbacks and AMREP digests disappointing quarterly numbers.

U.S. stock futures are pointing higher this Monday morning, and that means investors will be keeping a close eye on several companies reporting earnings or dealing with fresh news that could move their shares.

Earnings on Deck Before the Open

Wall Street expects MindWalk Holdings Corp. (HYFT) to report a quarterly loss of 1 cent per share on revenue of $4.00 million before the opening bell, according to data from Benzinga Pro. MindWalk Holdings shares fell 5.4% to close at $1.77 on Friday.

Clinical Trial Setback

Argenx SE (ARGX) disclosed that it has discontinued Phase 3 UplighTED studies of Efgartigimod SC in thyroid eye disease after futility review. Argenx shares fell 1.3% to close at $877.94 on Friday.

After-Hours Earnings Expected

Analysts are expecting Navan Inc. (NAVN) to post a quarterly loss of 25 cents per share on revenue of $182.04 million. The company will release quarterly earnings after the markets close. Navan shares gained 4.53% to $14.55 on Friday.

Analysts expect Champions Oncology Inc. (CSBR) to post quarterly earnings at 1 cent per share on revenue of $14.04 million after the closing bell. Champions Oncology shares surged 6.3% to close at $6.72 on Friday.

Friday's Disappointment

AMREP Corp. (AXR) reported downbeat results for the second quarter on Friday. The company posted quarterly earnings of 22 cents per share, which missed the analyst consensus estimate of 44 cents per share. The company reported quarterly sales of $9.398 million, which missed the analyst consensus estimate of $14.970 million. Amrep shares fell 4.1% to close at $20.16 on Friday.

Back to News

Five Stocks in the Spotlight as Earnings Season Continues

MarketDash Editorial Team
10 hours ago
With stock futures pointing higher Monday morning, investors are watching several companies reporting earnings results, including MindWalk Holdings, Navan, and Champions Oncology, while argenx deals with clinical trial setbacks and AMREP digests disappointing quarterly numbers.

U.S. stock futures are pointing higher this Monday morning, and that means investors will be keeping a close eye on several companies reporting earnings or dealing with fresh news that could move their shares.

Earnings on Deck Before the Open

Wall Street expects MindWalk Holdings Corp. (HYFT) to report a quarterly loss of 1 cent per share on revenue of $4.00 million before the opening bell, according to data from Benzinga Pro. MindWalk Holdings shares fell 5.4% to close at $1.77 on Friday.

Clinical Trial Setback

Argenx SE (ARGX) disclosed that it has discontinued Phase 3 UplighTED studies of Efgartigimod SC in thyroid eye disease after futility review. Argenx shares fell 1.3% to close at $877.94 on Friday.

After-Hours Earnings Expected

Analysts are expecting Navan Inc. (NAVN) to post a quarterly loss of 25 cents per share on revenue of $182.04 million. The company will release quarterly earnings after the markets close. Navan shares gained 4.53% to $14.55 on Friday.

Analysts expect Champions Oncology Inc. (CSBR) to post quarterly earnings at 1 cent per share on revenue of $14.04 million after the closing bell. Champions Oncology shares surged 6.3% to close at $6.72 on Friday.

Friday's Disappointment

AMREP Corp. (AXR) reported downbeat results for the second quarter on Friday. The company posted quarterly earnings of 22 cents per share, which missed the analyst consensus estimate of 44 cents per share. The company reported quarterly sales of $9.398 million, which missed the analyst consensus estimate of $14.970 million. Amrep shares fell 4.1% to close at $20.16 on Friday.